Wstęp
Ta strona zawiera kompleksową analizę znanej historii wykorzystywania informacji poufnych w firmie Thomas Gad. Insiderzy to członkowie kadry kierowniczej, dyrektorzy lub znaczący inwestorzy w spółce. Dokonywanie transakcji w ich firmach w oparciu o określone, niepubliczne informacje jest nielegalne. Nie oznacza to, że dokonywanie jakichkolwiek transakcji we własnych firmach jest nielegalne. Muszą jednak zgłaszać wszystkie transakcje do SEC za pośrednictwem formularza 4. Pomimo tych ograniczeń badania akademickie sugerują, że insiderzy – ogólnie rzecz biorąc – mają tendencję do osiągania lepszych wyników na rynku w swoich własnych firmach.
Średnia rentowność handlu
Średnia rentowność handlu to średni zwrot ze wszystkich zakupów na otwartym rynku dokonanych przez osobę mającą dostęp do informacji poufnych w ciągu ostatnich trzech lat. Aby to obliczyć, badamy każdy nieplanowany zakup na otwartym rynku dokonany przez insidera, z wyłączeniem wszystkich transakcji oznaczonych jako część planu handlowego 10b5-1. Następnie obliczamy średnią wydajność tych transakcji w ciągu 3, 6 i 12 miesięcy, uśredniając każdy z tych okresów, aby wygenerować ostateczny wskaźnik wydajności dla każdej transakcji. Na koniec uśredniamy wszystkie wskaźniki wydajności, aby obliczyć wskaźnik wydajności dla insidera. Na tej liście znajdują się wyłącznie insiderzy, którzy dokonali co najmniej trzech transakcji w ciągu ostatnich dwóch lat.
Jeśli rentowność handlu insiderów jest oznaczona notką„nie dotyczy”, oznacza to, że insider albo nie dokonał żadnych zakupów na otwartym rynku w ciągu ostatnich trzech lat, albo transakcje, których dokonał, są zbyt nowe, aby obliczyć wiarygodny wskaźnik wydajności.
Częstotliwość aktualizacji: codziennie
Spółki posiadające zgłoszone stanowiska osób mających dostęp do poufnych informacji
Z dokumentów SEC wynika, że Thomas Gad zgłosił udziały lub transakcje w następujących spółkach:
| Papier wartościowy | Nazwa | Najnowsze raporty dotyczące udziałów |
|---|---|---|
| US:YMAB / Y-mAbs Therapeutics, Inc. | CHIEF BUSINESS OFFICER, Director | 0 |
Jak interpretować wykresy
Poniższe wykresy przedstawiają notowania akcji papierów wartościowych po każdej niezaplanowanej transakcji na otwartym rynku dokonanej przez Thomas Gad. Nieplanowane transakcje to transakcje, które nie zostały dokonane w ramach planu handlowego 10b5-1. Notowania akcji przedstawiono na wykresie jako skumulowaną procentową zmianę ceny akcji. Na przykład, jeśli 1 stycznia 2019 r. dokonano transakcji poufnej, wykres pokaże dzienną procentową zmianę papieru wartościowego do dnia dzisiejszego. Jeżeli cena akcji wzrosłaby w tym czasie z 10 do 15 dolarów, skumulowana procentowa zmiana ceny akcji wyniosłaby 50%. Zmiana ceny z 10$ na 20$ będzie wynosić 100%, a zmiana ceny z 10$ na 5$ będzie wynosić -50%.
Ostatecznie staramy się określić, jak blisko transakcje insiderów korelują z nadmiernymi zwrotami (dodatnimi lub ujemnymi) z ceny akcji, aby sprawdzić, czy insider dostosowuje swoje transakcje w taki sposób, aby czerpać korzyści z informacji poufnych. Rozważmy sytuację, w której zrobił to ktoś z wewnątrz. W tej sytuacji oczekiwalibyśmy albo (a) dodatnich zwrotów po zakupach, albo (b) ujemnych zwrotów po sprzedaży. W przypadku (a) wykres ZAKUPU pokazywałby serię krzywych nachylonych w górę, wskazujących dodatnie zwroty po każdej transakcji zakupu. W przypadku (b) wykres SPRZEDAŻ pokazywałby serię krzywych o nachyleniu w dół, wskazujących ujemne zwroty po każdej transakcji sprzedaży.
Samo to jednak nie wystarczy, aby wyciągnąć wnioski. Gdyby np. cena akcji spółki przez wiele lat rosła niecyklicznie, to spodziewalibyśmy się, że wszystkie wykresy po zakupie będą wykazywały tendencję wzrostową. Podobnie niecykliczne spadki na przestrzeni wielu lat spowodowałyby spadek linii na wykresie po transakcjach. Żaden z tych wykresów nie sugeruje wykorzystywania informacji poufnych.
Najsilniejszym wskaźnikiem byłaby sytuacja, gdy cena akcji miała charakter wyjątkowo cykliczny, a na wykresie KUPNO występowały zarówno pozytywne sygnały na wykresie KUPNA, jak i negatywne na wykresie SPRZEDAŻY. Sytuacja ta wysoce sugerowałaby osobę mającą dostęp do informacji poufnych, która wykorzystywała transakcje w celu uzyskania korzyści finansowej.
Historia handlu insiderów
Ta tabela przedstawia pełną listę transakcji insiderów dokonanych przez firmę Thomas Gad ujawnioną Komisji Papierów Wartościowych (SEC).
| Data pliku | Data trans | Formularz | Ticker | Bezpieczeństwo | Kod | Akcje | Pozostałe akcje | Zmiana procent |
Cena udziału |
Wartość trans |
Pozostała Wartość |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
U - Other | -60 000 | 0 | -100,00 | 8,60 | -516 000 | ||
| 2025-09-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
U - Other | -67 681 | 0 | -100,00 | 8,60 | -582 057 | ||
| 2025-09-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -60 235 | 0 | -100,00 | ||||
| 2025-09-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
U - Other | -245 486 | 0 | -100,00 | 8,60 | -2 111 180 | ||
| 2025-06-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 103 000 | 305 721 | 50,81 | 2,00 | 206 000 | 611 442 | |
| 2025-03-11 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -10 810 | 202 721 | -5,06 | 5,23 | -56 536 | 1 060 231 | |
| 2025-01-22 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
A - Award | 32 000 | 213 531 | 17,63 | ||||
| 2024-09-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 22 831 | 181 531 | 14,39 | 4,38 | 100 000 | 795 106 | |
| 2024-09-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -30 000 | 67 681 | -30,71 | 12,97 | -389 100 | 877 823 | |
| 2024-09-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -65 000 | 97 681 | -39,96 | 13,47 | -875 550 | 1 315 763 | |
| 2024-06-11 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -35 000 | 162 681 | -17,71 | 12,00 | -420 000 | 1 952 172 | |
| 2024-06-11 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -35 000 | 197 681 | -15,04 | 12,03 | -421 050 | 2 378 102 | |
| 2024-05-23 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -7 351 | 232 681 | -3,06 | 13,00 | -95 563 | 3 024 853 | |
| 2024-05-23 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -25 000 | 240 032 | -9,43 | 12,00 | -300 000 | 2 880 384 | |
| 2024-03-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -3 900 | 158 700 | -2,40 | 16,44 | -64 116 | 2 609 028 | |
| 2024-01-22 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
A - Award | 22 100 | 162 600 | 15,73 | ||||
| 2023-12-26 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 50 000 | 140 500 | 55,25 | 2,00 | 100 000 | 281 000 | |
| 2023-12-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 000 | 265 032 | -15,87 | 6,61 | -330 500 | 1 751 862 | |
| 2023-12-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 000 | 315 032 | -13,70 | 6,83 | -341 500 | 2 151 669 | |
| 2023-12-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 000 | 365 032 | -12,05 | 6,58 | -329 000 | 2 401 911 | |
| 2023-11-22 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -75 000 | 415 032 | -15,31 | 5,31 | -397 988 | 2 202 367 | |
| 2023-11-22 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -75 000 | 490 032 | -13,27 | 5,30 | -397 395 | 2 596 484 | |
| 2023-01-19 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
A - Award | 40 500 | 90 500 | 81,00 | ||||
| 2022-05-19 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
A - Award | 60 000 | 60 000 | |||||
| 2022-02-09 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -64 276 | 565 032 | -10,21 | 6,96 | -447 117 | 3 930 476 | |
| 2022-02-09 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -125 863 | 629 308 | -16,67 | 7,01 | -882 891 | 4 414 407 | |
| 2022-02-09 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -91 031 | 755 171 | -10,76 | 7,59 | -691 180 | 5 733 862 | |
| 2022-02-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -101 104 | 846 202 | -10,67 | 7,70 | -778 531 | 6 516 009 | |
| 2022-02-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -35 060 | 947 306 | -3,57 | 7,90 | -277 027 | 7 485 138 | |
| 2022-02-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -8 000 | 153 000 | -4,97 | ||||
| 2022-02-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -8 000 | 50 000 | -13,79 | 10,15 | -81 161 | 507 255 |
| 2022-02-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 8 000 | 58 000 | 16,00 | 2,00 | 16 000 | 116 000 | |
| 2022-01-26 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -55 783 | 982 366 | -5,37 | 10,96 | -611 281 | 10 764 963 | |
| 2022-01-26 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -32 272 | 1 038 149 | -3,01 | 10,07 | -325 131 | 10 459 040 | |
| 2022-01-24 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -20 184 | 1 070 421 | -1,85 | 11,35 | -229 103 | 12 150 028 | |
| 2022-01-24 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 134 | 1 090 605 | -4,39 | 10,51 | -526 713 | 11 458 005 | |
| 2022-01-24 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -112 767 | 1 140 739 | -9,00 | 11,33 | -1 277 289 | 12 920 923 | |
| 2022-01-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -69 414 | 1 253 506 | -5,25 | 10,89 | -756 092 | 13 653 814 | |
| 2022-01-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -8 000 | 161 000 | -4,73 | ||||
| 2022-01-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -400 | 1 322 920 | -0,03 | 11,46 | -4 584 | 15 160 663 | |
| 2022-01-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -8 000 | 50 000 | -13,79 | 11,54 | -92 314 | 576 965 |
| 2022-01-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 8 000 | 58 000 | 16,00 | 2,00 | 16 000 | 116 000 | |
| 2021-12-16 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
A - Award | 110 000 | 110 000 | |||||
| 2021-12-16 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
G - Gift | 60 000 | 1 383 320 | 4,53 | ||||
| 2021-12-16 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
G - Gift | -60 000 | 1 323 320 | -4,34 | ||||
| 2021-12-08 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -10 000 | 1 383 320 | -0,72 | 17,58 | -175 832 | 24 323 192 | |
| 2021-12-08 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -4 000 | 1 393 320 | -0,29 | 16,50 | -65 982 | 22 983 510 | |
| 2021-12-08 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -40 000 | 1 397 320 | -2,78 | 16,48 | -659 260 | 23 029 930 | |
| 2021-12-01 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 437 320 | -0,28 | 16,98 | -67 912 | 24 402 963 |
| 2021-12-01 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -7 770 | 1 441 320 | -0,54 | 17,04 | -132 433 | 24 566 002 | |
| 2021-12-01 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -12 800 | 1 449 090 | -0,88 | 17,11 | -218 947 | 24 786 974 | |
| 2021-12-01 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -600 | 1 461 890 | -0,04 | 16,94 | -10 166 | 24 769 241 | |
| 2021-12-01 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -22 437 | 1 462 490 | -1,51 | 17,16 | -385 026 | 25 096 767 | |
| 2021-11-26 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -50 000 | 169 000 | -22,83 | ||||
| 2021-11-26 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 000 | 50 000 | -50,00 | 17,06 | -852 850 | 852 850 | |
| 2021-11-26 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 50 000 | 100 000 | 100,00 | 2,00 | 100 000 | 200 000 | |
| 2021-11-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 484 927 | -0,27 | 19,33 | -77 302 | 28 696 957 |
| 2021-11-01 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 488 927 | -0,27 | 24,82 | -99 261 | 36 948 021 |
| 2021-10-19 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 492 927 | -0,27 | 27,20 | -108 799 | 40 607 316 |
| 2021-10-04 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 496 927 | -0,27 | 28,26 | -113 054 | 42 308 546 |
| 2021-09-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 500 927 | -0,27 | 33,64 | -134 579 | 50 498 239 |
| 2021-09-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -50 000 | 219 000 | -18,59 | ||||
| 2021-09-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 50 000 | 50 000 | 2,00 | 100 000 | 100 000 | ||
| 2021-09-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 000 | 1 504 927 | -3,22 | 33,18 | -1 658 915 | 49 930 919 | |
| 2021-08-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -1 779 | 1 554 927 | -0,11 | 28,96 | -51 527 | 45 036 906 | |
| 2021-08-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -22 111 | 1 556 706 | -1,40 | 29,33 | -648 527 | 45 658 965 | |
| 2021-08-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 578 817 | -0,25 | 29,14 | -116 544 | 46 000 412 |
| 2021-08-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -1 110 | 1 582 817 | -0,07 | 31,01 | -34 426 | 49 089 645 | |
| 2021-08-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 583 927 | -0,25 | 33,73 | -134 927 | 53 428 709 |
| 2021-07-21 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 587 927 | -0,25 | 32,47 | -129 875 | 51 558 084 |
| 2021-07-08 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 591 927 | -0,25 | 31,87 | -127 465 | 50 728 664 |
| 2021-07-02 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 595 927 | -0,25 | 33,86 | -135 446 | 54 040 323 |
| 2021-06-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 599 927 | -0,25 | 35,80 | -143 217 | 57 284 266 |
| 2021-06-01 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 603 927 | -0,25 | 36,95 | -147 813 | 59 270 396 |
| 2021-05-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 607 927 | -0,25 | 34,07 | -136 290 | 54 785 932 |
| 2021-04-28 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -7 000 | 269 000 | -2,54 | ||||
| 2021-04-28 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 000 | 0 | -100,00 | 27,96 | -195 730 | |
| 2021-04-28 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 000 | 7 000 | 2,00 | 14 000 | 14 000 | |
| 2021-04-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -7 000 | 276 000 | -2,47 | ||||
| 2021-04-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 611 927 | -0,25 | 26,60 | -106 388 | 42 872 422 |
| 2021-04-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 000 | 0 | -100,00 | 26,61 | -186 253 | |
| 2021-04-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 000 | 7 000 | 2,00 | 14 000 | 14 000 | |
| 2021-04-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -9 000 | 283 000 | -3,08 | ||||
| 2021-04-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -6 000 | 1 615 927 | -0,37 | 30,27 | -181 615 | 48 912 818 |
| 2021-04-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -9 000 | 0 | -100,00 | 30,26 | -272 331 | |
| 2021-04-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 9 000 | 9 000 | 2,00 | 18 000 | 18 000 | |
| 2021-03-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -7 000 | 292 000 | -2,34 | ||||
| 2021-03-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 1 621 927 | -0,25 | 36,78 | -147 102 | 59 647 176 |
| 2021-03-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 000 | 0 | -100,00 | 36,79 | -257 554 | |
| 2021-03-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 000 | 7 000 | 2,00 | 14 000 | 14 000 | |
| 2021-03-12 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
J - Other | 1 029 927 | 1 625 927 | 172,81 | ||||
| 2021-03-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -9 000 | 299 000 | -2,92 | ||||
| 2021-03-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -6 000 | 596 000 | -1,00 | 35,50 | -213 029 | 21 160 861 |
| 2021-03-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -9 000 | 0 | -100,00 | 35,51 | -319 611 | |
| 2021-03-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 9 000 | 9 000 | 2,00 | 18 000 | 18 000 | |
| 2021-02-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -7 000 | 308 000 | -2,22 | ||||
| 2021-02-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 602 000 | -0,66 | 47,09 | -188 367 | 28 349 203 |
| 2021-02-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 000 | 0 | -100,00 | 47,08 | -329 556 | |
| 2021-02-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 000 | 7 000 | 2,00 | 14 000 | 14 000 | |
| 2021-02-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -7 000 | 315 000 | -2,17 | ||||
| 2021-02-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 606 000 | -0,66 | 41,97 | -167 888 | 25 435 032 |
| 2021-02-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 000 | 0 | -100,00 | 41,99 | -293 897 | |
| 2021-02-03 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 000 | 7 000 | 2,00 | 14 000 | 14 000 | |
| 2021-01-21 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -7 000 | 322 000 | -2,13 | ||||
| 2021-01-21 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 610 000 | -0,65 | 46,56 | -186 230 | 28 400 136 |
| 2021-01-21 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 000 | 0 | -100,00 | 46,51 | -325 563 | |
| 2021-01-21 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 000 | 7 000 | 2,00 | 14 000 | 14 000 | |
| 2021-01-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -7 000 | 329 000 | -2,08 | ||||
| 2021-01-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 614 000 | -0,65 | 49,31 | -197 248 | 30 277 568 |
| 2021-01-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 000 | 0 | -100,00 | 49,36 | -345 509 | |
| 2021-01-07 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 000 | 7 000 | 2,00 | 14 000 | 14 000 | |
| 2020-12-30 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -7 000 | 336 000 | -2,04 | ||||
| 2020-12-30 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 000 | 0 | -100,00 | 51,98 | -363 833 | |
| 2020-12-30 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 000 | 7 000 | 2,00 | 14 000 | 14 000 | |
| 2020-12-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -7 000 | 343 000 | -2,00 | ||||
| 2020-12-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -7 000 | 0 | -100,00 | 53,01 | -371 065 | |
| 2020-12-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | X | 7 000 | 7 000 | 2,00 | 14 000 | 14 000 | |
| 2020-12-16 |
|
4 | VYMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 618 000 | -0,64 | 52,89 | -211 546 | 32 683 795 |
| 2020-12-16 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
A - Award | 91 450 | 91 450 | |||||
| 2020-12-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 000 | 0 | -100,00 | 51,17 | -2 558 640 | ||
| 2020-12-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 50 000 | 50 000 | 2,00 | 100 000 | 100 000 | ||
| 2020-12-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -50 000 | 350 000 | -12,50 | ||||
| 2020-12-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -50 000 | 350 000 | -12,50 | ||||
| 2020-12-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 000 | 0 | -100,00 | 50,75 | -2 537 620 | ||
| 2020-12-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 50 000 | 50 000 | 2,00 | 100 000 | 100 000 | ||
| 2020-12-02 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 622 000 | -0,64 | 51,42 | -205 685 | 31 984 049 |
| 2020-11-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 626 000 | -0,63 | 46,17 | -184 672 | 28 901 105 |
| 2020-11-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 630 000 | -0,63 | 43,69 | -174 769 | 27 526 086 |
| 2020-10-19 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 634 000 | -0,63 | 39,15 | -156 604 | 24 821 671 |
| 2020-10-02 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 638 000 | -0,62 | 38,88 | -155 524 | 24 806 142 |
| 2020-09-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 642 000 | -0,62 | 40,81 | -163 225 | 26 197 580 |
| 2020-09-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -22 569 | 450 000 | -4,78 | ||||
| 2020-09-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -22 569 | 0 | -100,00 | 41,00 | -925 426 | ||
| 2020-09-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 22 569 | 22 569 | 2,00 | 45 138 | 45 138 | ||
| 2020-09-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -13 571 | 472 569 | -2,79 | ||||
| 2020-09-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -13 571 | 0 | -100,00 | 40,33 | -547 331 | ||
| 2020-09-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 13 571 | 13 571 | 2,00 | 27 142 | 27 142 | ||
| 2020-09-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
M - Exercise | -13 860 | 486 140 | -2,77 | ||||
| 2020-09-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -13 860 | 0 | -100,00 | 41,58 | -576 360 | ||
| 2020-09-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
M - Exercise | 13 860 | 13 860 | 2,00 | 27 720 | 27 720 | ||
| 2020-09-02 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 646 000 | -0,62 | 41,60 | -166 390 | 26 872 050 |
| 2020-08-19 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 650 000 | -0,61 | 40,35 | -161 392 | 26 226 200 |
| 2020-08-13 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -13 000 | 654 000 | -1,95 | 39,51 | -513 636 | 25 839 867 | |
| 2020-08-13 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -37 000 | 667 000 | -5,26 | 40,06 | -1 482 042 | 26 716 818 | |
| 2020-08-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 704 000 | -0,56 | 36,51 | -146 026 | 25 700 576 |
| 2020-07-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 708 000 | -0,56 | 40,06 | -160 229 | 28 360 568 |
| 2020-07-06 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 712 000 | -0,56 | 42,04 | -168 178 | 29 935 684 |
| 2020-06-16 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 716 000 | -0,56 | 43,45 | -173 811 | 31 112 205 |
| 2020-06-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 720 000 | -0,55 | 41,61 | -166 444 | 29 959 848 |
| 2020-05-29 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 000 | 724 000 | -6,46 | 39,01 | -1 950 460 | 28 242 661 | |
| 2020-05-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 774 000 | -0,51 | 39,65 | -158 596 | 30 688 326 |
| 2020-05-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -50 000 | 778 000 | -6,04 | 39,04 | -1 951 935 | 30 372 109 | |
| 2020-05-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 828 000 | -0,48 | 32,35 | -129 404 | 26 786 711 |
| 2020-04-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 832 000 | -0,48 | 29,43 | -117 711 | 24 483 930 |
| 2020-03-18 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 836 000 | -0,48 | 18,01 | -72 041 | 15 056 527 |
| 2020-03-04 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 840 000 | -0,47 | 29,18 | -116 713 | 24 509 772 |
| 2020-02-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 844 000 | -0,47 | 32,78 | -131 133 | 27 669 021 |
| 2020-02-11 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 848 000 | -0,47 | 33,03 | -132 121 | 28 009 610 |
| 2020-01-29 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 852 000 | -0,47 | 35,06 | -140 224 | 29 867 627 |
| 2020-01-15 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 856 000 | -0,47 | 30,90 | -123 612 | 26 452 968 |
| 2020-01-09 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
A - Award | 130 000 | 130 000 | |||||
| 2019-12-31 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
J - Other | -201 | 1 030 356 | -0,02 | ||||
| 2019-12-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 860 000 | -0,46 | 31,54 | -126 176 | 27 127 926 |
| 2019-12-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
G - Gift | -8 000 | 864 000 | -0,92 | ||||
| 2019-12-04 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 872 000 | -0,46 | 32,48 | -129 930 | 28 324 827 |
| 2019-11-19 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 876 000 | -0,45 | 28,41 | -113 658 | 24 891 014 |
| 2019-11-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 880 000 | -0,45 | 30,10 | -120 418 | 26 491 960 |
| 2019-10-22 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 884 000 | -0,45 | 27,59 | -110 351 | 24 387 527 |
| 2019-10-08 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 888 000 | -0,45 | 25,21 | -100 848 | 22 388 256 |
| 2019-09-17 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 892 000 | -0,45 | 30,59 | -122 376 | 27 289 759 |
| 2019-09-05 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 896 000 | -0,44 | 25,77 | -103 081 | 23 090 099 |
| 2019-08-20 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 900 000 | -0,44 | 27,70 | -110 805 | 24 931 080 |
| 2019-08-06 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 904 000 | -0,44 | 21,78 | -87 106 | 19 685 866 |
| 2019-07-23 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 908 000 | -0,44 | 22,54 | -90 177 | 20 470 134 |
| 2019-07-10 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 912 000 | -0,44 | 22,40 | -89 592 | 20 426 885 |
| 2019-06-25 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 916 000 | -0,43 | 21,77 | -87 098 | 19 945 350 |
| 2019-06-11 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 920 000 | -0,43 | 22,79 | -91 166 | 20 968 272 |
| 2019-06-04 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -4 000 | 924 000 | -0,43 | 20,03 | -80 121 | 18 507 997 |
| 2019-05-29 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -6 000 | 928 000 | -0,64 | 20,21 | -121 252 | 18 753 674 |
| 2019-05-14 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | X | -6 000 | 934 000 | -0,64 | 20,61 | -123 647 | 19 247 779 |
| 2019-04-11 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -150 000 | 940 000 | -13,76 | 25,80 | -3 870 000 | 24 252 000 | |
| 2019-04-11 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -800 | 1 090 000 | -0,07 | 26,93 | -21 545 | 29 355 444 | |
| 2019-04-11 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
S - Sale | -99 200 | 1 090 800 | -8,34 | 26,02 | -2 581 184 | 28 382 616 | |
| 2018-12-13 |
|
4 | YMAB |
Y-mAbs Therapeutics, Inc.
Employee Stock Option (right to buy) |
A - Award | 107 500 | 107 500 | |||||
| 2018-09-20 | 3 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
3 410 557 | ||||||||
| 2018-09-20 | 3 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
3 251 114 | ||||||||
| 2018-09-20 | 3 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
3 410 557 | ||||||||
| 2018-09-20 | 3 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
3 251 114 | ||||||||
| 2018-09-20 | 3 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
3 410 557 | ||||||||
| 2018-09-20 | 3 | YMAB |
Y-mAbs Therapeutics, Inc.
Common Stock |
3 251 114 |